Anorexia/ Cachexia Clinical Trials & Research at Providence Medical Group

Anorexia-cachexia syndrome (ACS) is a complex metabolic disorder commonly observed in advanced cancer patients, characterized by loss of appetite, unintentional weight loss, and muscle wasting. It significantly impacts patients' quality of life, treatment outcomes, and overall survival.

Providence Medical Group is currently enrolling patients for the following Anorexia/ Cachexia clinical trials:

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia

Treatment agent: NGM120
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | ClinicalTrials.gov
Sponsor: NGM Biopharmaceuticals, Inc
Location: Providence Cancer Center, Santa Rosa, CA

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Loss and Fatigue (RIVER-mPDAC)

Treatment agent: Ponsegromab (PF-06946860)
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | ClinicalTrials.gov
Sponsor: Pfizer
Location: Providence Cancer Center, Santa Rosa, CA